Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalMEX:BMRN 80 Days Inventory is 601.35 as of Mar. 2026, which is 2% below its 10-year median of 610.53. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,505.40 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 638 Biotechnology companies, BioMarin Pharmaceutical ranks worse than 85.58% on this metric.
The historical rank and industry rank for BioMarin Pharmaceutical's Days Inventory or its related term are showing as below:
MEX:BMRN'
s Days Inventory Range Over the Past 10 Years
Min: 479.97 Med: 610.53 Max: 735.94
Current: 630.27
During the past 13 years, BioMarin Pharmaceutical's highest Days Inventory was 735.94. The lowest was 479.97. And the median was 610.53.
MEX:BMRN's Days Inventory is ranked worse than 85.58% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs MEX:BMRN: 630.27
BioMarin Pharmaceutical's Days Inventory
declined
from Mar. 2025 (762.07) to Mar. 2026 (601.35).
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioMarin Pharmaceutical's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioMarin Pharmaceutical's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.68.
BioMarin Pharmaceutical (MEX:BMRN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BioMarin Pharmaceutical's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioMarin Pharmaceutical's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BioMarin Pharmaceutical Days Inventory Related Terms
BioMarin Pharmaceutical Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs CYTK, ARWR, TECH: Days Inventory Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Days Inventory distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (MEX:BMRN) has a Days Inventory of 601.35 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioMarin Pharmaceutical and its competitors. This is near median its historical median of 610.53. Over the past decade, BioMarin Pharmaceutical's Days Inventory has ranged from 479.97 to 735.94. According to the industry distribution chart, BioMarin Pharmaceutical ranks #546 out of 638 companies in the Biotechnology industry, placing it in the top 85.6%.
Is BioMarin Pharmaceutical's Days Inventory too high?
BioMarin Pharmaceutical's current Days Inventory of 601.35 is near median its 10-year median of 610.53. Over the past 10 years, this metric has ranged from a low of 479.97 to a high of 735.94. The Biotechnology industry median Days Inventory is 183.20. BioMarin Pharmaceutical's value of 601.35 is 228.3% above this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #546 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Days Inventory compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #546 out of 638 companies for Days Inventory. This places BioMarin Pharmaceutical in the lower half of its industry. The industry median Days Inventory is 183.20. BioMarin Pharmaceutical's value of 601.35 is 228.3% above this benchmark. Historically, BioMarin Pharmaceutical's own Days Inventory has ranged from 479.97 to 735.94 over the past decade. While the company's 10-year median is 610.53 vs. the industry median of 183.20, BioMarin Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current Days Inventory of 601.35 is 228.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current Days Inventory is 601.35, which is near median its own 10-year median of 610.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,505.40, compared to a current price of MXN959.00 — trading 36.3% below its estimated fair value. The current Days Inventory is 601.35, which is near median its 10-year median of 610.53 and 228.3% above the Biotechnology industry median of 183.20. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Days Inventory is 601.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 36.3% below its estimated GF Value™ of MXN1,505.40.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
Days Inventory: 601.35 (near median its 10-year median of 610.53)
GF Value™: MXN1,505.40 vs. price of MXN959.00 (36.3% below fair value)
Industry Position: 228.3% above the Biotechnology median (#546 of 638)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
